Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or addition...
Saved in:
| Main Authors: | Mamoudou Maiga, Nisheeth Agarwal, Nicole C Ammerman, Radhika Gupta, Haidan Guo, Marama C Maiga, Shichun Lun, William R Bishai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0030749&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01) -
FDA APPROVES NEW HEMOPHILIA DRUG
by: article Editorial
Published: (2025-02-01) -
Safety evaluation of the food enzyme phosphodiesterase I from the non‐genetically modified Leptographium procerum strain FDA
by: EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP), et al.
Published: (2024-04-01) -
FDA approved injection drug against schizophrenia
by: article Editorial
Published: (2023-07-01) -
IL-15: from discovery to FDA approval
by: Zihai Li, et al.
Published: (2025-02-01)